[
PET Radiopharmacy
PSMA
[18F]F-
[18F]F-PSMA-1007
prostate cancer
quality assurance
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
22 Jun 2021
22 Jun 2021
Historique:
received:
20
05
2021
revised:
10
06
2021
accepted:
15
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Radiopharmaceuticals targeting the prostate-specific membrane antigen (PSMA) has become the gold standard for PET imaging of prostate cancer. [
Identifiants
pubmed: 34206461
pii: ph14070599
doi: 10.3390/ph14070599
pmc: PMC8308622
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Cell Biochem. 2004 Feb 15;91(3):528-39
pubmed: 14755683
Molecules. 2015 Jul 16;20(7):12913-43
pubmed: 26193247
Bioconjug Chem. 2012 Apr 18;23(4):688-97
pubmed: 22369515
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
Theranostics. 2020 Jan 1;10(1):1-16
pubmed: 31903102
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688
pubmed: 27889802
Pharmaceuticals (Basel). 2017 Sep 27;10(4):
pubmed: 28953234
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1400-6
pubmed: 26971788
Appl Radiat Isot. 2008 Mar;66(3):295-302
pubmed: 17996453